Traders watch earnings announcements keenly, as changes in a company’s financials can be a good indication whether a company is on the right track, or headed the wrong way.

ULURU Inc. (ULU) is scheduled to release its earnings results Tuesday. The company currently has an earnings per share ratio (EPS trailing twelve months) of - .18 and investors are hoping to see that number change. Let’s take a look at the performance of the stock since its previous earnings release.

{loadposition link_newslink1}

In the past three months, the stock has posted a -25.39% loss in terms of stock price. Over the same period, the Drug Delivery industry group has returned a combined 2.07% gain.

So the eyes of investors turn to this new round of earnings.

Now, good earnings don’t always lead to higher stock prices, but keeping up on earnings is still a vital part of your fundamental stock analysis. Also note that companies often change earnings dates, so you should double-check them often.

When looking at earnings, it’s very helpful to see how stocks compare to others in its industry group. And even though two stocks may not be direct competitors, many analysts and institutional investors still compare them and evaluate them relative to other stocks in their group.  

ULU is in the Drug Delivery industry group where it competes for investor dollars with companies like Emisphere Technologies, Inc. (EMIS), which released its earnings on 05/07 and last reported a -29.15% decline in quarter-over-quarter EPS.

Another industry peer, Novadel Pharma Inc. (NVD) released its earnings on 11/14 and last reported a 47.31% gain in QOQ EPS.

Hospira Inc. (HSP) is the stock with the biggest market cap in the Drug Delivery industry at $7.65B. It closed yesterday at $47.16

To better understand how to evaluate earnings announcements and the affect they have on your portfolio, be sure to read Earnings Announcements and EPS.

{loadposition link_nowtime}

{loadposition followus} 

Investors watch earnings filings with particular interest, as changes in a company’s ratios can be a good indication whether a company is on the right track, or headed the wrong way.

Flamel Technologies SA (FLML) is scheduled to release its earnings results Monday. The company currently has an earnings per share ratio (EPS trailing twelve months) of - .31 and investors are hoping to see that number change. Let’s take a look at the performance of the stock since its previous earnings release.

{loadposition link_newslink1}

In the past three months, the stock has posted a -9.71% loss in terms of stock price. Over the same period, the Drug Delivery industry group has returned a combined 2.07% gain.

So the eyes of investors turn to this new round of earnings.

Now, good earnings don’t always lead to higher stock prices, but keeping up on earnings is still a vital part of your fundamental stock analysis. Also note that companies often change earnings dates, so you should double-check them often.

When looking at earnings, it’s very helpful to see how stocks compare to others in its industry group. And even though two stocks may not be direct competitors, many analysts and institutional investors still compare them and evaluate them relative to other stocks in their group.  

FLML is in the Drug Delivery industry group where it competes for investor dollars with companies like KV Pharmaceutical Co. (KV-A), which released its earnings on 11/17 and last reported a 89.03% gain in quarter-over-quarter EPS.

Another industry peer, PetMed Express Inc. (PETS) released its earnings on 10/19 and last reported a 11.97% gain in QOQ EPS.

Hospira Inc. (HSP) is the stock with the biggest market cap in the Drug Delivery industry at $7.65B. It closed yesterday at $47.16

To better understand how to evaluate earnings announcements and the affect they have on your portfolio, be sure to read Earnings Announcements and EPS.

{loadposition link_nowtime}

{loadposition followus} 

Investors watch earnings announcements closely, as changes in a company’s financials can be a good indication whether a company is on the right track, or headed the wrong way.

pSivida Corp. (PSDV) is scheduled to release its earnings results Thursday. The company currently has an earnings per share ratio (EPS trailing twelve months) of - .14 and investors are hoping to see that number change. Let’s take a look at the performance of the stock since its previous earnings release.

{loadposition link_newslink1}

In the past three months, the stock has posted a 30.20% gain in terms of stock price. Over the same period, the Drug Delivery industry group has returned a combined 2.70% gain.

So the eyes of investors turn to this new round of earnings.

Now, good earnings don’t always lead to higher stock prices, but keeping up on earnings is still a vital part of your fundamental stock analysis. Also note that companies often change earnings dates, so you should double-check them often.

When looking at earnings, it’s very helpful to see how stocks compare to others in its industry group. And even though two stocks may not be direct competitors, many analysts and institutional investors still compare them and evaluate them relative to other stocks in their group.  

PSDV is in the Drug Delivery industry group where it competes for investor dollars with companies like Columbia Laboratories Inc. (CBRX), which released its earnings on 11/05 and last reported a -15.74% decline in quarter-over-quarter EPS.

Another industry peer, Penwest Pharmaceuticals Co. (PPCO) released its earnings on 11/05 and last reported a 69.30% gain in QOQ EPS.

Hospira Inc. (HSP) is the stock with the biggest market cap in the Drug Delivery industry at $7.80B. It closed yesterday at $48.09

To better understand how to evaluate earnings announcements and the affect they have on your portfolio, be sure to read Earnings Announcements and EPS.

{loadposition link_nowtime}

{loadposition followus}